A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes

被引：0
|
作者：
Wu, Anfan
List, Alan
Lush, Richard
Bretz, Kelly
Knight, Robert
Lau, Henry
Zeldis, Jerry
机构：
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4854
引用
收藏
页码：299B / 299B
页数：1
相关论文
共 50 条
  • [1] Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
    Stasi, R
    Abruzzese, E
    Lanzetta, G
    Terzoli, E
    Amadori, S
    ANNALS OF ONCOLOGY, 2005, 16 (12) : 1921 - 1927
  • [2] Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
    van de Loosdrecht, Arjan A.
    Westers, Theresia M.
    Westra, August H.
    Draeger, Angelika M.
    van der Velden, Vincent H. J.
    Ossenkoppelel, Gert J.
    BLOOD, 2008, 111 (03) : 1067 - 1077
  • [3] Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes A Randomized Trial
    Angelucci, Emanuele
    Li, Junmin
    Greenberg, Peter
    Wu, Depei
    Hou, Ming
    Montano Figueroa, Efreen Horacio
    Guadalupe Rodriguez, Maria
    Dong, Xunwei
    Ghosh, Jagannath
    Izquierdo, Miguel
    Garcia-Manero, Guillermo
    ANNALS OF INTERNAL MEDICINE, 2020, 172 (08) : 513 - +
  • [4] Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes
    Ghaderi, Afshin
    Nodehi, Sayyed Reza Safaee
    Bakhtiari, Tahereh
    Aslani, Mona
    Aghazadeh, Zahra
    Matsuo, Hidenori
    Rehm, Bernd H. A.
    Cuzzocrea, Salvatore
    Mirshafiey, Abbas
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07) : 879 - 888
  • [5] A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Beyne-Rauzy, Odile
    Mufti, Ghulam
    Mittelman, Moshe
    Muus, Petra
    Boekhorst, Peter Te
    Sanz, Guillermo
    del Canizo, Consuelo
    Guerci-Bresler, Agnes
    Nilsson, Lars
    Platzbecker, Uwe
    Luebbert, Michael
    Quesnel, Bruno
    Cazzola, Mario
    Ganser, Arnold
    Bowen, David
    Schlegelberger, Brigitte
    Aul, Carlo
    Knight, Robert
    Francis, John
    Fu, Tommy
    Hellstrom-Lindberg, Eva
    BLOOD, 2011, 118 (14) : 3765 - 3776
  • [6] Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
    Scharenberg, Christian
    Giai, Valentina
    Pellagatti, Andrea
    Saft, Leonie
    Dimitriou, Marios
    Jansson, Monika
    Jadersten, Martin
    Grandien, Alf
    Douagi, Iyadh
    Neuberg, Donna S.
    LeBlanc, Katarina
    Boultwood, Jacqueline
    Karimi, Mohsen
    Jacobsen, Sten Eirik W.
    Woll, Petter S.
    Hellstrom-Lindberg, Eva
    HAEMATOLOGICA, 2017, 102 (03) : 498 - 508
  • [7] Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis
    Lian, Xin-yue
    Zhang, Zhi-hui
    Deng, Zhao-qun
    He, Pin-fang
    Yao, Dong-ming
    Xu, Zi-jun
    Wen, Xiang-mei
    Yang, Lei
    Lin, Jiang
    Qian, Jun
    PLOS ONE, 2016, 11 (11):
  • [8] Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion
    Oliva, Esther N.
    Cuzzola, Maria
    Nobile, Francesco
    Ronco, Francesca
    D'Errigo, Maria Grazia
    Lagana, Carmelo
    Morabito, Fortunato
    Galimberti, Sara
    Cortelezzi, Agostino
    Spiriti, Maria A. Aloe
    Specchia, Giorgina
    Poloni, Antonella
    Breccia, Massimo
    Ghio, Riccardo
    Finelli, Carlo
    Iacopino, Pasquale
    Alimena, Giuliana
    Latagliata, Roberto
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (03) : 231 - 235
  • [9] Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes
    Schanz, Julie
    Jung, Heike
    Woermann, Bernhard
    Gassmann, Winfried
    Petersen, Thomas
    Hinke, Axel
    Haase, Detlef
    LEUKEMIA RESEARCH, 2009, 33 (09) : 1183 - 1188
  • [10] Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study
    Poloni, Antonella
    Raaschou-Jensen, Klas
    Mohedo, Francisca Hernandez
    Paolini, Stefania
    Oliva, Esther Natalie
    Buccisano, Francesco
    Vasconcelos, Alberto
    Kim, Iris
    Makwana, Aidan
    Bernasconi, David
    Rosettani, Barbara
    Prebet, Thomas
    Santini, Valeria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (03) : e131 - e142
12345